Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary

In brief

To evaluate the efficacy and safety of 26-weeks of treatment with riociguat vs. placebo in patients with symptomatic PH (pulmonary hypertension) associated with IIP (idiopathic interstitial pneumonias).

Key facts

Study ID
NCT02138825
Run by
Bayer
People needed
147
Starts
2014-06-04
Expected to finish
2016-09-14
Last updated by the study team
2017-12-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.